Ticagrelor or prasugrel in patients with acute coronary syndromes - New England Journal of Medicine - 2019
Brief Summary:
In patients with acute coronary syndrome (ACS), for whom an invasive evaluation is planned, prasugrel was associated with a 2.4% absolute reduction in the primary outcome of death, nonfatal MI, and stroke, driven primarily by reduction in nonfatal myocardial infarction (although there was also numerically lower all-cause mortality). Stent thrombosis was rare in both groups, but numerically lower with prasugrel. Major bleeding rates were similar in both groups.Reference: http://www.ncbi.nlm.nih.gov/pubmed/31475799
Comments
Post a Comment
Drop your thoughts here, we would love to hear from you